影像科学与光化学 ›› 2022, Vol. 40 ›› Issue (6): 1545-1549.DOI: 10.7517/issn.1674-0475.220806

• 综述与论文 • 上一篇    下一篇

间苯三酚联合盐酸利托君对前置胎盘患者胎盘血流指标及血清EphA5、SFlt-1的影响

李婧, 杨红   

  1. 北京四季青医院妇产科, 北京 100097
  • 收稿日期:2022-08-06 出版日期:2022-11-23 发布日期:2022-11-15
  • 通讯作者: 李婧
  • 基金资助:
    江苏省卫生计生委2018年度医学科研课题(2018139)

Effects of Phloroglucinol Combined with Ritodrine Hydrochloride on Placental Blood Flow Indexes and Serum Eph A5, SFlt-1 in Patients with Placenta previa

LI Jing, YANG Hong   

  1. Department of Obstetrics and Gynecology, Beijing Sijiqing Hospital, Beijing 100097, P. R. China
  • Received:2022-08-06 Online:2022-11-23 Published:2022-11-15

摘要: 本研究探讨间苯三酚联合盐酸利托君对前置胎盘患者血清促红细胞生成素产生肝细胞受体(Eph)A5、可溶性血管内皮细胞生长因子受体-1(SFlt-1)及胎盘血流(能量超声)指标的影响。将96例前置胎盘患者按照治疗方案不同分为单药组和联合组,各48例。单药组给予盐酸利托君,联合组给予间苯三酚联合盐酸利托君。比较两组保胎成功率、妊娠足月率、阴道止血时间、孕周延长时间、药物起效时间、1min Apgar评分、血清甲胎蛋白(AFP)、肌酸激酶(CK)、Eph A5、SFlt-1、胎盘血流(能量超声)指标[血管流量指数(VFI)、血管化指数(VI)、流量指数(FI)]及安全性。联合组保胎成功率、妊娠足月率均高于单药组(P<0.05);联合组孕周延长时间高于单药组(P<0.05);治疗后联合组血清CK、AFP、SFlt-1水平均低于单药组,Eph A5水平高于单药组(P<0.05);治疗后联合组VFI、VI均低于单药组,两组FI比较,差异无统计学意义(P>0.05);两组总不良反应发生率比较,差异无统计学意义(P>0.05)。间苯三酚联合盐酸利托君可提高前置胎盘患者治疗效果,并能有效改善胎盘血流,促进胚胎发育,降低SFlt-1水平,提高Eph A5水平。

关键词: 间苯三酚, 盐酸利托君, 前置胎盘, Eph A5, SFlt-1, 胎盘血流

Abstract: This study investigated the effect of phloroglucinol combined with ritodrine hydrochloride on serum erythropoietin-producing hepatocyte receptor (Eph) A5, soluble vascular endothelial growth factor receptor-1 (SFlt-1) and placental blood flow indicators (energy ultrasound) in patients with placenta previa. A total of 96 patients with placenta previa were divided into single drug group and combination group according to different treatment plans, 48 cases in each group. The single drug group was given ritodrine hydrochloride, and the combination group was given phloroglucinol combined with ritodrine hydrochloride. The success rate of miscarriage protection, term rate of pregnancy, vaginal bleeding time, prolonged gestational age, drug onset time, 1 min Apgar score, serum alpha-fetoprotein (AFP), creatine kinase (CK), Eph A5, SFlt-1, placental blood flow (energy ultrasound) indexes [vascular flow index (VFI), vascularization index (VI), flow index (FI)] and safety. The success rate of miscarriage preservation and the full-term pregnancy rate in the combination group were higher than that in the single drug group (P<0.05). The prolongation time of gestational weeks in the combination group was higher than that in the single drug group (P<0.05). After treatment, the levels of serum CK, AFP and sFlt-1 in the combination group were lower than those in the single drug group, and the level of Eph A5 was higher than that in the single drug group (P<0.05). VFI and VI in the combination group were lower than those in the single-drug group after treatment, and there was no significant difference in FI between the two groups (P>0.05). There was no significant difference in the total adverse reaction rate between the two groups (P>0.05). Phloroglucinol combined with ritodrine hydrochloride can improve the therapeutic effect of patients with placenta previa, and can effectively improve placental blood flow and promote embryonic development, decreased SFlt-1 levels, increased Eph A5 levels.

Key words: hallucinogenic, ritodrine hydrochloride, placenta previa, Eph A5, SFlt-1, placental blood flow